Graft vs Host Disease Clinical Trials

218 clinical trials for Graft vs Host Disease across international registries, including 32 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants — RECRUITING
• Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children — RECRUITING
• Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — RECRUITING · PHASE1
• Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD — RECRUITING · NA
• A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant — RECRUITING · PHASE2
• Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease — RECRUITING · PHASE4
• Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT. — RECRUITING · PHASE4
• A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT — RECRUITING · PHASE2
• Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD — RECRUITING · PHASE2
• Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis — RECRUITING · PHASE2
• Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation — RECRUITING · PHASE1
• A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant — RECRUITING · NA
• Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) — RECRUITING
• Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial — RECRUITING · NA
• Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation — RECRUITING
• Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain. — RECRUITING
• IS-free Treg HaploHCT — RECRUITING · PHASE1
• Vitamin A Supplementation in Allogeneic Stem Cell Transplantation. — RECRUITING · PHASE2
• A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — RECRUITING · PHASE1
• MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy — RECRUITING · NA
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AXATILIMAB AND CORTICOSTEROIDS AS INITIAL TREATMENT FOR CHRONIC GRAFT VERSUS-HOST DISEASE — RECRUITING · PHASE3
• Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD — RECRUITING · PHASE1
• AN OPEN LABEL, MULTI-CENTER, PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLOBAL NOVARTIS OR INCYTE SPONSORED RUXOLITINIB (INC424) STUDY OR A STUDY OF RUXOLITINIB IN COMBINATION EITHER WITH PANOBINOSTAT (LBH589) OR SIREMADLIN (HDM201) OR RINETERKIB (LTT462), AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT — RECRUITING · PHASE4
• A PHASE 2, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AXATILIMAB IN COMBINATION WITH RUXOLITINIB IN PARTICIPANTS WITH NEWLY DIAGNOSED CHRONIC GRAFT-VERSUS-HOST DISEASE — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO EVALUATE EFFICACY AND SAFETY OF BELUMOSUDIL IN COMBINATION WITH CORTICOSTEROIDS VERSUS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH NEWLY DIAGNOSED CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED MULTICENTER STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE — RECRUITING · PHASE3
• oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort — RECRUITING
• A RANDOMIZED, OPEN-LABEL PHASE II CLINICAL TRIAL COMPARING DURABLE OVERALL RESPONSE RATE (DOR) AT 56 DAYS IN PATIENTS WITH STEROID-RESISTANT SEVERE ACUTE GVHD AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATED WITH DECIDUAL STROMAL CELLS (DSC) OR BEST AVAILABLE TREATMENT (BAT) — RECRUITING · PHASE2
• A RANDOMIZED PILOT TRIAL COMPARING ANTI-THYMOCYTE GLOBULIN (ATG) WITH ATG PLUS POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR PROPHYLAXIS AGAINST ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE (GVHD) IN MATCHED DONOR HEMATOPOIETIC CELL TRANSPLANTS (HCT) — RECRUITING
• EXTENDED TREATMENT PROTOCOL FOR SUBJECTS CONTINUING TO BENEFIT FROM IBRUTINIB AFTER COMPLETION OF IBRUTINIB CLINICAL TRIALS — RECRUITING
• PHASE 1/2 DOSE FINDING, SAFETY AND EFFICACY STUDY OF IBRUTINIB IN PEDIATRIC SUBJECTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) — RECRUITING · PHASE1
• CONTINUOUS ALLOREACTIVE T CELL DEPLETION AND REGULATORY T CELL EXPANSION FOR THE TREATMENT OF STEROID-REFRACTORY OR DEPENDENT CHRONIC GVHD - A MULTICENTER PHASE II CLINICAL TRIAL — RECRUITING · PHASE2
• Pediatric cGVHD Symptom Scale — ACTIVE_NOT_RECRUITING
• Emerging Indications for Hyperbaric Oxygen Treatment — NOT_YET_RECRUITING · PHASE4
• Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells — WITHDRAWN
• High Dose Chemotherapy and Autologous Transplant for Breast Cancer — COMPLETED · PHASE2
• Optoacoustic Detection of Inflammation Using MSOT Device — TERMINATED · NA
• Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation — COMPLETED · PHASE1
• Horizons Chronic Graft-Versus-Host-Disease Study — ACTIVE_NOT_RECRUITING · NA
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression — COMPLETED · PHASE1
• Evaluation of the Impact of Reduced Immunosuppression — COMPLETED
• Chronic GVHD Response Measures Validation — ACTIVE_NOT_RECRUITING
• A multicenter, open-label, randomized, phase II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT) — OTHER · PHASE2
• CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome — SUSPENDED · PHASE2
• Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation — COMPLETED · PHASE2
• A PHASE 2 STUDY OF BELUMOSUDIL COMBINED WITH RUXOLITINIB AS SECOND LINE THERAPY TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER STEROID FAILURE (BELRUX) — NOT_YET_RECRUITING · PHASE2
• Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD — ACTIVE_NOT_RECRUITING · PHASE2
• Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation — ACTIVE_NOT_RECRUITING · PHASE1
• Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases — ACTIVE_NOT_RECRUITING · NA
• Multidisciplinary Intervention In Chronic GVHD — ACTIVE_NOT_RECRUITING · NA

Refine this search